Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

Marie-Laure Chaix, Isabelle Charreau, Claire Pintado, Constance Delaugerre, Nadia Mahjoub, Laurent Cotte, Catherine Capitant, François Raffi, Eric Cua, Gilles Pialoux, Cécile Tremblay, Laurence Meyer, Jean-Michel Molina, ANRS IPERGAY Study Group, C Pintado, B Loze, C Delaugerre, P Charbonneau, C Gatey, D Ponscarme, P Penot, L Niedbalski, R Veron, J Delgado, E Dalle, S Parlier, I Madelaine, J Fonsart, M Danet, N Mahjoub, N Mezreb, K Moudachirou, S Morel, G Conort, F Lorho, M Meunier, W Rozenbaum, J M Molina, J Chas, C Monfort, J Foucoin, B Boissavy, S Cousseau, S Huon, M Danet, A Djessima, V Berrebi, A Adda, S le Nagat, L Zarka, J Berdougo, G Pialoux, C Chidiac, N Mzoughi, F Clement, A Decouty, C Chapolard, M Godinot, C Adouard-Groslafeige, J Koffi, A Pansu, A Becker, S Pailhes, F Bonnet, F Jeanblanc, C Brochier, X Teruin, S Rouby, L Gilly, L Cotte, C Etienne, F Tolonin, S Breaud, V Péchenot, S Bagge, T Cepitelli, P M Roger, E Rosenthal, E Cua, A Cheret, P Cornavin, S Vandamme, J Lambec, N Dumon, O Leclanche, T Huleux, R Biekre, O Robineau, H Melliez, H Bazus, A Pasquet, C Bernaud, M Besnier, B Bonnet, N Hall, M Cavellec, H Hue, L Larmet, M Colas, R Choquet, F Raffi, C Beauvais, P Arlotto, C Fortin, A Talbot, A Chamberland, A McKenzie, M Blanchette, R Rousseau, K Montheuth, J Otis, D Thompson, M Morin, M Wainberg, C Tremblay, L Meyer, C Capitant, I Charreau, B Guillon, E Netzer, N Leturque, J Binesse, V Foubert, M Saouzanet, F Euphrasie, D Carette, J P Aboulker, B Spire, L Sagaon-Teyssier, M Suzan, L Fressard, B Demoulin, G Cattin, N Lorente, V Doré, L Marchand, S Le Mestre, A Mennecier, E Choucair, N Etien, A Diallo, S Gibowski, M-C Simon, J-F Delfraissy, J M Le Gall, S Morel, V Pechenot, S Bagge, A Djessima Taba, M Danet, K Moudachirou, B Dos Santos, J Lambec, S Rouby, X Teruin, N Dumon, V Coquelin, P Brunet, L Gilly, T Cepitelli, R Porion, D Rojas Castro, B Spire, Jean-Michel Molina, Mark Wainberg, Benoit Trottier, Cécile Tremblay, Jean-Guy Baril, Gilles Pialoux, Laurent Cotte, Antoine Chéret, Armelle Pasquet, Eric Cua, Michel Besnier, Willy Rozenbaum, Christian Chidiac, Constance Delaugerre, Nathalie Bajos, Julie Timsit, Gilles Peytavin, Julien Fonsart, Isabelle Durand-Zaleski, Laurence Meyer, Jean-Pierre Aboulker, Bruno Spire, Marie Suzan-Monti, Gabriel Girard, Daniela Rojas Castro, Marie Préau, Michel Morin, David Thompson, Catherine Capitant, Lucie Marchand, Véronique Doré, Marie-Christine Simon, Isabelle Charreau, Joanne Otis, France Lert, Alpha Diallo, Séverine Gibowski, Cecile Rabian, Marie-Laure Chaix, Isabelle Charreau, Claire Pintado, Constance Delaugerre, Nadia Mahjoub, Laurent Cotte, Catherine Capitant, François Raffi, Eric Cua, Gilles Pialoux, Cécile Tremblay, Laurence Meyer, Jean-Michel Molina, ANRS IPERGAY Study Group, C Pintado, B Loze, C Delaugerre, P Charbonneau, C Gatey, D Ponscarme, P Penot, L Niedbalski, R Veron, J Delgado, E Dalle, S Parlier, I Madelaine, J Fonsart, M Danet, N Mahjoub, N Mezreb, K Moudachirou, S Morel, G Conort, F Lorho, M Meunier, W Rozenbaum, J M Molina, J Chas, C Monfort, J Foucoin, B Boissavy, S Cousseau, S Huon, M Danet, A Djessima, V Berrebi, A Adda, S le Nagat, L Zarka, J Berdougo, G Pialoux, C Chidiac, N Mzoughi, F Clement, A Decouty, C Chapolard, M Godinot, C Adouard-Groslafeige, J Koffi, A Pansu, A Becker, S Pailhes, F Bonnet, F Jeanblanc, C Brochier, X Teruin, S Rouby, L Gilly, L Cotte, C Etienne, F Tolonin, S Breaud, V Péchenot, S Bagge, T Cepitelli, P M Roger, E Rosenthal, E Cua, A Cheret, P Cornavin, S Vandamme, J Lambec, N Dumon, O Leclanche, T Huleux, R Biekre, O Robineau, H Melliez, H Bazus, A Pasquet, C Bernaud, M Besnier, B Bonnet, N Hall, M Cavellec, H Hue, L Larmet, M Colas, R Choquet, F Raffi, C Beauvais, P Arlotto, C Fortin, A Talbot, A Chamberland, A McKenzie, M Blanchette, R Rousseau, K Montheuth, J Otis, D Thompson, M Morin, M Wainberg, C Tremblay, L Meyer, C Capitant, I Charreau, B Guillon, E Netzer, N Leturque, J Binesse, V Foubert, M Saouzanet, F Euphrasie, D Carette, J P Aboulker, B Spire, L Sagaon-Teyssier, M Suzan, L Fressard, B Demoulin, G Cattin, N Lorente, V Doré, L Marchand, S Le Mestre, A Mennecier, E Choucair, N Etien, A Diallo, S Gibowski, M-C Simon, J-F Delfraissy, J M Le Gall, S Morel, V Pechenot, S Bagge, A Djessima Taba, M Danet, K Moudachirou, B Dos Santos, J Lambec, S Rouby, X Teruin, N Dumon, V Coquelin, P Brunet, L Gilly, T Cepitelli, R Porion, D Rojas Castro, B Spire, Jean-Michel Molina, Mark Wainberg, Benoit Trottier, Cécile Tremblay, Jean-Guy Baril, Gilles Pialoux, Laurent Cotte, Antoine Chéret, Armelle Pasquet, Eric Cua, Michel Besnier, Willy Rozenbaum, Christian Chidiac, Constance Delaugerre, Nathalie Bajos, Julie Timsit, Gilles Peytavin, Julien Fonsart, Isabelle Durand-Zaleski, Laurence Meyer, Jean-Pierre Aboulker, Bruno Spire, Marie Suzan-Monti, Gabriel Girard, Daniela Rojas Castro, Marie Préau, Michel Morin, David Thompson, Catherine Capitant, Lucie Marchand, Véronique Doré, Marie-Christine Simon, Isabelle Charreau, Joanne Otis, France Lert, Alpha Diallo, Séverine Gibowski, Cecile Rabian

Abstract

We evaluated the impact of on-demand oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) on herpes simplex virus (HSV)-1/2 incidence among men who have sex with men (MSM) enrolled in the ANRS IPERGAY trial. Serum samples were tested at baseline and at the last visit for HSV-1/2 antibodies. Overall HSV-1 incidence was 11.7 per 100 person-years; 16.2 and 7.8 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .19). Overall HSV-2 incidence was 7.6 per 100 person-years; 8.1 and 7.0 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .75). On-demand oral PrEP with TDF/FTC failed to reduce HSV-1/2 incidence in this population.

Keywords: HSV1/2 incidence; HSV1/2 prevalence; MSM; PrEP; TDF/FTC.

References

    1. Looker KJ, Magaret AS, May MT, et al. . Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS ONE 2015; 10:e0140765.
    1. Looker KJ, Elmes JAR, Gottlieb SL, et al. . Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis 2017; 17:1303–16.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168–74.
    1. Andrei G, Lisco A, Vanpouille C, et al. . Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10:379–89.
    1. Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med 2015; 373:530–9.
    1. Celum C, Morrow RA, Donnell D, et al. . Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med 2014; 161:11–9.
    1. Marcus JL, Glidden DV, McMahan V, et al. . Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One 2014; 9:e91513.
    1. Molina JM, Capitant C, Spire B, et al. . On-demand preexposure prophylaxis in men at high risk for HIV-1 Infection. N Engl J Med 2015; 373:2237–46.
    1. LeGoff J, Grésenguet G, Gody C, et al. . Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings. Clin Vaccine Immunol 2011; 18:1191–3.
    1. Patterson KB, Prince HA, Kraft E, et al. . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011; 3:112re4.
    1. Tan D. Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health 2012; 4:341–50.
    1. Hendrix CW, Chen BA, Guddera V, et al. . MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013; 8:e55013.
    1. Tan DH, Kaul R, Raboud JM, Walmsley SL. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS 2011; 25:207–10.
    1. Mark KE, Wald A, Magaret AS, et al. . Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141–9.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner